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Abstract
The adapter protein TRAF6 is critical for mediating signal transduction from members of the IL-1R/TLR and TNFR
superfamilies. The TRAF6 RING finger domain functions as an ubiquitin E3 ligase capable of generating non-degradative
K63-linked ubiquitin chains. It is believed that these chains serve as docking sites for formation of signaling complexes, and
that K63-linked autoubiquitination of TRAF6 is essential for formation and activation of a complex involving the kinase TAK1
and its adapters, TAB1 and TAB2. In order to assess independently the E3 ligase and ubiquitin substrate functions of TRAF6,
we generated, respectively, RING domain and complete lysine-deficient TRAF6 mutants. We found that while the TRAF6
RING domain is required for activation of TAK1, it is dispensable for interaction between TRAF6 and the TAK1-TAB1-TAB2
complex. Likewise, lysine-deficient TRAF6 was found to interact with the TAK1-TAB1-TAB2 complex, but surprisingly was
also found to be fully competent to activate TAK1, as well as NFkB and AP-1 reporters. Furthermore, lysine-deficient TRAF6
rescued IL-1-mediated NFkB and MAPK activation, as well as IL-6 elaboration in retrovirally-rescued TRAF6-deficient
fibroblasts. Lysine-deficient TRAF6 also rescued RANKL-mediated NFkB and MAPK activation, and osteoclastogenesis in
retrovirally-rescued TRAF6-deficient bone marrow macrophages. While incapable of being ubiquitinated itself, we
demonstrate that lysine-deficient TRAF6 remains competent to induce ubiquitination of IKKc/NEMO. Further, this NEMO
modification contributes to TRAF6-mediated activation of NFkB. Collectively, our results suggest that while TRAF6
autoubiquitination may serve as a marker of activation, it is unlikely to underpin RING finger-dependent TRAF6 function.
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Introduction
Non-conventional K63-linked ubiquitination has gained atten-
tion in recent years as a mechanism of protein scaffold building for
complex formation during signal transduction. Upon activation,
HECT or RING finger domain-containing E3 ubiquitin ligases
affix these non-degradative ubiquitin chains to protein substrates,
which then serve as recruitment platforms for downstream
signaling mediators [1,2]. The close proximity of factors generated
by these scaffolds is believed to promote otherwise energetically
inefficient conformational adaptations or phosphorylation events
[1,2,3]. A particularly notable K63-specific RING finger E3
ubiquitin ligase is TNFR-associated factor 6 (TRAF6), which was
identified as having such activity upon being isolated from an IkB
kinase (IKK)-activating complex [4,5]. Like most other TRAFs,
TRAF6 is composed of an N-terminal RING finger domain, a
series of zinc fingers, a coiled-coil domain, and a C-terminal
TRAF domain. TRAF6 is unique from other TRAFs in that it
utilizes a distinct interaction motif, which is found in its upstream
activators [6]. As such, TRAF6 has been implicated in directing
the signals from representative members of a diverse array of
receptor families, including the TNF receptor superfamily
(TNFRSF), IL-1R/Toll-like receptor superfamily (IL-1R/
TLRSF), TGFbR, IL-17R and IL-25R, and the NOD-like pattern
recognition receptors [7,8,9,10,11,12,13]. TRAF6 activation leads
to downstream activation of PI3K, the mitogen-activated protein
kinase (MAPK) cascade, and the transcription factor families
NFkB, NFAT, and IRF [12,14,15]. Numerous biochemical and
genetic studies have revealed mechanistic insights into TRAF6
utilization of ubiquitination to propagate diverse signals. To date,
the most prominent model holds that upon activation via TRAF6
homo-oligimerization, the RING finger ubiquitin E3 ligase
domain complexes with a K63-specific E2 conjugating enzyme
(Ubc13/Uev1a, or possibly UbcH7) to mediate attachment of
non-degradative K63-linked ubiquitin chains to TRAF6 sub-
strates, specifically TRAF6 itself [4,16]. These chains recruit
factors, like the adapters TAB2/3, which contain atypical zinc
finger domains with a special affinity for binding K63-linked
ubiquitin chains [17]. As part of a pre-formed complex, TAB2/3
bring TAB1 and the putative IKK and MKK kinase TAK1 to
TRAF6 [5]. It is believed that TAK1 is then activated via a trans-
phosphorylation event made possible by the close proximity
generated by complex formation [1,18]. Activated TAK1 then
phosphorylates downstream factors. However, the complexities
involved in studying ubiquitin-mediated signaling events have
made certain aspects of this model difficult to formally demon-
strate. For instance, putative ubiquitin targets are often ubiquiti-
nated with both K48-linked degradative and K63-linked non-
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the propensity of ubiquitination complexes to generate chains of
varying lengths at a given modification site in vivo, making
detection of ubiquitination by traditional size separation tech-
niques challenging. Attempts to genetically manipulate lysine
acceptor sites on protein substrates with the intention of ablating
E3 ligase-specific ubiquitination may result in dramatically
decreased modification, while failing to entirely eliminate
physiologically relevant ubiquitin chains that happen to be affixed
at low levels or heterotypic lengths. Lastly, while autoubiquitina-
tion is often readily detected in the context of in vitro ubiquitina-
tion, these assays feature a well-recognized caveat of increased E3
ligase promiscuity in the absence of alternative targets, such that
the same autoubiquitination event observed in vitro may not have
physiologic relevance in vivo [19,20]. Therefore, we sought to
investigate, through genetic approaches, the relationship between
TRAF6 RING finger ubiquitin E3 ligase activity, TRAF6
(auto)ubiquitination (for the purpose of clarity we will refer to all
K63-linked ubiquitination of TRAF6 as autoubiquitination, while
recognizing that additional ubiquitin E3 ligases may be involved in
TRAF6 K63-linked modification in vivo) and recruitment and
activation of downstream signaling. We found that while the
TRAF6 RING finger domain is required for activation of TAK1,
it is dispensable for interaction between TRAF6 and the TAK1-
TAB1-TAB2 complex. Surprisingly, we found that TRAF6
autoubiquitination was dispensable for both interaction with,
and activation of, the TAK1 signaling complex. Further, TRAF6
autoubiquitination, but not RING finger function, was found to be
dispensable for IL-1- or RANKL-dependent elaboration of IL-6,
or osteoclastogenesis, respectively. Finally, TRAF6 autoubiquiti-
nation was found not to be required for TRAF6 to ubiquitinate an
alternative target, specifically IKKc (NEMO).
Results
TRAF6 associates with the TAK1-TAB1-TAB2 complex in
the absence of a functional TRAF6 RING finger domain
It has previously been demonstrated that TRAF6 RING finger
function, K63-linked ubiquitination, and the ubiquitin-binding
domain of TAB2 are required for TRAF6-mediated activation of
downstream signaling pathways [17]. It is believed that TRAF6
autoubiquitination serves as a point of recruitment for TAB2, and
hence TAB1 and TAK1. If so, we reasoned that overexpression of
a TRAF6 mutant possessing a defective RING finger (C70A), and
therefore incapable of autoubiquitination, should not inhibit
NFkB activation induced by co-overexpression of TAK1 and its
activator, TAB1. Rather, in reporter assays for NFkB, we found
that while overexpression of wild-type TRAF6 in conjunction with
TAB1 and TAK1 enhanced reporter activity over TAB1 and
TAK1 alone, overexpression of RING finger-mutant TRAF6
(C70A) caused a greater than 2-fold reduction in activity (Fig. 1A).
To assess the importance of the TRAF6 RING finger function to
Figure 1. TRAF6 associates with the TAK1-TAB1-TAB2 complex in the absence of a functional TRAF6 RING finger domain. (A) 293T
cells were transfected with NFkB-luciferase, 40 ng TAB1 and TAK1, and 400 ng of empty vector (EV), TRAF6, or TRAF6 C70A as indicated. Cell lysates
were analyzed by luciferase reporter assay. Values indicate fold increase over background and are normalized against a b-galactosidase internal
standard. (B) 293T cells were transfected with equal amounts (1 mg) of epitope-tagged TRAF6 (FLAG) or TAK1 (Myc) expression plasmids and
subjected to immunoprecipitation (IP) with anti-FLAG agarose. IP and whole cell extracts (WCE) were immunoblotted with anti-Myc or anti-FLAG as
indicated. (C), (D), (E) 293T cells were transfected with WT or C70A FLAG-TRAF6(1-358)-Gyrase B as indicated, plus an equal amount of Myc-tagged
TAB2 (C), TAB1 (D) or TAK1 (E). Cell lysates were processed and analyzed as in (B).
doi:10.1371/journal.pone.0004064.g001
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immunoprecipiation assay, and found that another TRAF6
mutant containing a defective RING finger (C85A/H87A)
interacted more strongly with TAK1 than did wild-type TRAF6
(Fig. 1B). Like other TRAF proteins, TRAF6 forms homo- and
heterotypic interactions via a C-terminal TRAF domain [21]. To
exclude the possibility that a full-length TRAF6 RING mutant
might compensate for defective complex formation through
interactions with endogenous TRAF proteins, we generated
mutants in which the C-terminus of TRAF6 is replaced with the
artificial oligomerization domain of bacterial Gyrase B. Again, we
found that RING-mutant TRAF6 interacted as well, or better with
TAB2 (Fig. 1C), TAB1 (Fig. 1D), and TAK1 (Fig. 1E). Given that
TRAF6 autoubiquitination requires a functional RING finger,
these observations challenge the putative relationship between
TRAF6 autoubiquitination and recruitment of the TAK1
signaling complex to TRAF6.
A lysine-deficient TRAF6 N-terminus-Gyrase B fusion
protein interacts with and activates TAK1, and induces
NFkB and AP-1 reporter activity
Like many E3 ubiquitin ligases, TRAF6 has the capacity to
autoubiquitinate in vitro [4], (Fig. S1). Physiologic relevance of
TRAF6 autoubiquitination has been inferred from the dual
observations that 1) TRAF6 autoubiquitination is detected in vivo
upon engagement of TRAF6-dependent receptors, and 2) the
TRAF6 RING finger is required for propagating downstream
signal transduction. Recent efforts have been made to map the
lysines residue(s) on TRAF6 targeted during in vitro autoubiqui-
tination [22]. However, it remains unclear whether, or in what
pattern, TRAF6 might combine with other K63-specific E3
ubiquitin ligases to ubiquitinate TRAF6 in vivo. Therefore, we
sought to divorce the RING finger function of TRAF6 from its
capacity to serve as a substrate for ubiquitination. We employed a
mutagenesis approach targeting individual lysine residues, which
form isopeptide bonds with the carboxyl-terminal glycine 76 of
ubiquitin, to ablate TRAF6 autoubiquitination during in vivo
overexpression. However, we were only able to achieve partial
reduction in ubiquitination, possibly due to modification of
TRAF6 at multiple sites. Therefore, reasoning that we could
focus on the N-terminus, due to its ability to activate downstream
signaling when fused to Gyrase B, we simultaneously mutated all
N-terminal TRAF6 lysine residues (K32-348) on both full-length
and (1-358)-Gyrase B fusion versions of TRAF6 (Fig. 2A). We
tested the ability of the full-length TRAF6 (K32-348R) mutant to
autoubiquitinate in an in vitro ubiquitination assay and found that
K63-specific modification of TRAF6 was reduced to a level similar
to that of the TRAF6 RING finger mutant (C70A) (Fig. 2B). By
utilizing the TRAF6(1-358)-Gyrase B mutant (DK) to assess
interaction with TAK1 in 293T cells, we found that DK interacted
with TAK1 more strongly than wild-type TRAF6, though less
strongly than C70A (Fig. 2C), demonstrating dispensability of
TRAF6 autoubiquitination for complex formation with TAK1. In
the IL-1 signaling pathway, optimal TAK1-mediated activation of
JNK and NFkB requires phosphorylation of TAK1 at T187 (Fig.
S2). To assess the ability of TRAF6 mutants to activate TAK1, we
transfected low levels of TRAF6(1-358)-Gyrase B mutants and
induced oligomerization using the drug Coumermycin A1. While
all TRAF6 constructs exhibited interaction with TAK1 in the
absence of drug, and only the RING mutant failed to activate
TAK1 in the presence of drug, the DK mutant exhibited enhanced
activation of TAK1 in comparison to wild-type TRAF6, even in
the absence of drug treatment (Fig. 2D), suggesting that TRAF6
autoubiquitination may be dispensable for activation of TAK1-
mediated signaling. The various TRAF6-Gyrase B mutants were
then tested in reporter assays for NFkB and AP-1, and consistent
with its apparent enhanced ability to activate TAK1, the DK
mutant induced both NFkB (Fig. 2E) and AP-1 (Fig. 2F) reporters
to higher levels than wild-type TRAF6.
A lysine-deficient mutant TRAF6 rescues IL-1-mediated
NFkB and MAPK activation, as well as IL-6 production, in
TRAF6-deficient fibroblasts
To assess the requirement for TRAF6 autoubiquitination
during physiologic receptor signaling, we generated TRAF6-
deficient fibroblast cell lines retrovirally-rescued with either
FLAG-tagged wild-type, RING finger mutant (C70A), or total
lysine-deficient (K32-518R) TRAF6 (Fig. 3A). Anti-FLAG immu-
noprecipitation of these proteins was carried out, followed by an in
vitro ubiquitination assay which demonstrated not only that neither
C70A nor K32-518R could autoubiquitinate, but also that a
mixture of the two was incapable of autoubiquitination in trans
(Fig. 3B), suggesting the importance of TRAF6 oligimerization for
E3 ligase activity. IL-1R signaling in TRAF6-deficient fibroblasts
is completely defective. In vivo, induction of high molecular weight
TRAF6, in response to IL-1, treatment was detected in fibroblast
cell lines expressing wild-type, but not C70A or K32-518R
versions of TRAF6 (Fig. 3C), though in vivo expression levels of
TRAF6 K32-518R were consistently much lower than those of
wild-type TRAF6. Regardless, TRAF6 K32-518R was capable of
activating the kinases TAK1 and IKK in response to IL-1 in a
manner similar to wild-type TRAF6 (Fig. 3D). IL-1-dependent
activation of the MAPKs JNK and p38, and phosphorylation and
degradation of the NFkB inhibitor IkBa were also normal in
TRAF6 K32-518R-rescued cells (Fig. 3E). Though activation of
these key downstream signaling pathways in the absence of
TRAF6 autoubiquitination appeared normal, TRAF6-mediated
gene regulation involves complex coordination of multiple
transcription factor families, leaving the possibility that genetic
regulation by TRAF6 K32-518R might be defective. To address
this possibility, we assayed elaboration of the inflammatory
cytokine IL-6 by retrovirally-rescued fibroblasts in response to
IL-1 treatment, and found that while TRAF6 C70A failed to
induce IL-6 production, TRAF6 K32-518R-rescued cells pro-
duced IL-6 at slightly higher levels than cells rescued with wild-
type TRAF6 (Fig. 3F).
Lysine-deficient mutant TRAF6 rescues RANKL-mediated
NFkB and MAPK activation, as well as osteoclastogenesis
in TRAF6-deficient BMM
In addition to mediating IL-1R/TLRSF signaling via interac-
tions with IRAK, TRAF6 propagates TNFRSF signaling through
direct receptor binding. To examine the role of TRAF6
autoubiquitination in TNFRSF signaling, we generated retrovi-
rally-rescued TRAF6-deficient bone marrow macrophages ex-
pressing TRAF6 K32-518R, and treated with the TNFSF member
RANKL. Again, we found that lysine-deficient TRAF6 was
capable of activating the NFkB, JNK, and p38 pathways (Fig. 4A),
despite considerably diminished protein expression. RANKL
treatment in vitro is sufficient for BMM to develop into osteoclasts
in a TRAF6-dependent manner [23]. We found that TRAF6-
deficient BMM rescued with K32-518R, but not C70A were
capable of undergoing osteoclastogenesis similarly to wild-type-
rescued BMM (Fig. 4B). This observation was confirmed
quantitatively by assaying expression of the osteoclast marker
tartrate resistant acid phosphatase (TRAP) (Fig. 4C) and total
counts of large multi-nucleated cells (Fig. 4D). These data confirm
Autoubiquitination-Null TRAF6
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absence of TRAF6 autoubiquitination.
Lysine-deficient TRAF6 N-terminus-Gyrase B fusion
protein is competent to mediate TRAF6-specific ubiquitin
modification of NEMO
Substantial evidence exists for the general role of K63-linked
ubiquitination in promoting TRAF6-mediated signal transduction,
and while the TRAF6 RING finger domain is essential, the
dispensability of TRAF6 autoubiquitination opened the possibility
that the critical function of the RING domain is unrelated to
ubiquitin E3 ligase activity. Therefore, we sought to identify an
example of TRAF6 RING-mediated ubiquitination that occurs
independently of TRAF6 autoubiquitination. IKKc, the IKK
regulatory component also known as NEMO, is ubiquitinated in
response to TRAF6-dependent IL-1R/TLRSF stimulation [7],
and has been shown to be a K63-linked target of TRAF6 E3 ligase
activity in in vitro ubiquitination assays [22]. Consistent with these
observations, we found that upon treatment with IL-1, NEMO
immunoprecipitated from wild-type, but not TRAF6-deficient
fibroblasts, was ubiquitinated (Fig. 5A). To determine the
specificity of the NEMO modification, we co-transfected NEMO
with either TRAF6, or various TRAF6-associated factors (TRAF2,
TRAF5, constitutively-active IKKb (IKKbEE), TAK1/TAB1,
MEKK3, ASK1) known to act downstream of, or parallel to,
TRAF6-dependent signaling pathways [24,25,26,27,28]. We
found that despite the association of these various factors with
Figure 2. A lysine-deficient TRAF6 N-terminus-Gyrase B fusion protein interacts with and activates TAK1, and induces NFkB and AP-
1 reporter activity. (A) Generation of mutant versions of murine TRAF6 containing lysine (K) to arginine (R) mutations in the RING finger, zinc finger,
and coiled-coil domains (TRAF6 K32-348R) (top), or in the RING finger, zinc finger, and coiled-coil domains, but with the TRAF6-C domain replaced
with the Gyrase B artificial oligomerization domain (TRAF6(1-358)DK-Gyrase B) (bottom). (B) 293T cells were transfected with the indicated full-length
versions of FLAG-TRAF6, then lysates were immunoprecipitated with FLAG and subjected to in vitro ubiquitination in the presence or absence of ATP
using recombinant WT, K48-only, or K63-only ubiquitin. Unmodified and modified TRAF6 were detected by immunoblotting with anti-TRAF6. (C) 293T
cells were transfected with equal amounts (1 mg) of epitope-tagged TAK1 (Myc) in combination with either wild-type (WT), RING mutant (C70A), or
lysine-deficient (DK) TRAF6(1-358)-Gyrase B (FLAG) expression plasmids, and subjected to immunoprecipitation (IP) with anti-FLAG agarose. IP and
whole cell extracts (WCE) were immunoblotted with anti-Myc or anti-FLAG as indicated. (D) 293T cells were transfected with 10 ng of TAK1 in
combination with either wild-type (WT), RING mutant (C70A), or lysine-deficient (DK) TRAF6(1-358)-Gyrase B (FLAG) expression plasmids, and left
untreated or treated for 5 minutes with Coumermycin A before being harvested and subjected to IP with anti-FLAG agarose. IP and whole cell
extracts (WCE) were immunoblotted with anti-phospho TAK1 (T187), anti-TAK1, or anti-FLAG as indicated. (E), (F) 293T cells were transfected with
NFkB-luciferase (E) or AP-1-luciferase (F) plus WT, C70A, or K32-348R TRAF6(1-358)-Gyrase B as indicated. Cell lysates were analyzed by luciferase
reporter assay. Values indicate fold increase over background and are normalized against a b-galactosidase internal standard.
doi:10.1371/journal.pone.0004064.g002
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distinct modification of NEMO (Fig. 5B). Having identified a clear
TRAF6-inducible modification of NEMO, we sought to determine
whether it required either the TRAF6 RING finger domain or
ubiquitination of TRAF6. Using co-expression of NEMO with
TRAF6(1-358)-Gyrase B fusion constructs containing either
RING (C70A) or total lysine (DK) mutations, we found that while
the RING finger was required for NEMO modification, TRAF6
autoubiquitination was dispensable. To confirm that the modifi-
cation identified was in fact ubiquitination, we excised the
modified band from a preparative gel and subjected it to
nanoLC-MS/MS mass spectrometry, and identified an m/z
signature consistent with ubiquitination at NEMO K285
(Fig. 5D), which is consistent with previous reports [7,29]. We
generated a NEMO K285R mutant and compared TRAF6-
mediated modification of NEMO in the presence or absence of
lysine 285. Confirming the likely role of TRAF6 in ubiquitinating
NEMO independently of TRAF6 autoubiquitination, we found
that co-expression of either wild-type TRAF6 or TRAF6 DK with
NEMO K285R resulted in a complete abrogation of the TRAF6-
dependent modification observed on wild-type NEMO (Fig. 5E).
TRAF6-associated ubiquitination of NEMO is required for
optimal IL-1-mediated activation of NFkB
Lack of a requirement for TRAF6 autoubiquitination in
TRAF6 RING finger-dependent signaling suggests that alternative
physiologic targets of TRAF6 E3 ligase activity must exist. To
confirm the relevance of TRAF6-mediated NEMO ubiquitination
to physiologic NFkB activation, we retrovirally rescued NEMO-
deficient fibroblasts with wild-type or K285R NEMO and treated
with IL-1. We found that despite normal TAK1 activation, and
nearly normal phosphorylation of IkBa, activation of IKKa/b was
considerably diminished, and degradation of IkBa was slightly
reduced (Fig. 6A). To determine whether these signaling defects
affected NFkB-dependent cytokine production, we assayed
supernatant from the IL-1-treated fibroblasts for IL-6 production,
and found a greater than 50% reduction in fibroblasts rescued
with K285R as compared to wild-type NEMO. These observa-
Figure 3. A lysine-deficient mutant TRAF6 rescues IL-1-mediated NFkB and MAPK activation, as well as IL-6 production, in TRAF6-
deficient fibroblasts. (A) A mutant version of full-length TRAF6 containing lysine (K) to arginine (R) mutations at all lysine residues (referred to as
TRAF6 K32-518R or TRAF6 DK) was generated, and mutations are depicted in relation to TRAF6 domain location. (B) TRAF6-deficient fibroblasts were
retrovirally-rescued with the indicated full-length versions of FLAG-TRAF6, then lysates immunoprecipitated with FLAG and subjected to in vitro
ubiquitination in the presence or absence of ATP using recombinant K63-only ubiquitin. The last two lanes represent C70A and K32-518R lysates
mixed 1:1 prior to immunoprecipitation to assess trans-ubiquitination potential of TRAF6 monomers. Unmodified and modified TRAF6 were detected
by immunoblotting with anti-TRAF6. (C) Cell lines used in (B) were treated for 5 minutes with IL-1b, then lysed in the presence of N-ethyl maleimide
(NEM) and subjected to immunoblotting with anti-TRAF6 to detect both unmodified and high molecular weight forms of TRAF6. (D), (E) TRAF6-
deficient fibroblasts retrovirally-rescued with the indicated full-length versions of FLAG-TRAF6 were treated as indicated with IL-1b, then lysed and
subjected to immunoblotting against the activated phosphorylated forms of TAK1 (D), IKKa/b (D) IkBa (E), JNK (E), and p38 (E). (F) TRAF6-deficient
fibroblasts retrovirally-rescued with the indicated full-length versions of FLAG-TRAF6 were left untreated or treated for 12 hours with IL-1b.
Supernatants were collected and assayed by ELISA for IL-6 production. Values are normalized to crystal violet assays of the cell culture plates.
doi:10.1371/journal.pone.0004064.g003
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NEMO is physiologically relevant, but also that TRAF6-
dependent signaling likely involves targets of TRAF6 E3 ligase
activity beyond TRAF6 itself.
Discussion
The non-conventional RING finger E3 ligase activity of TRAF6
is critical for activating downstream signaling in the key
inflammatory and developmental pathways IL-1R and RANK,
respectively. TRAF6 autoubiquitination is commonly used as an
activation marker for RING finger activity, and it is currently held
that K63-linked ubiquitin chains on TRAF6 serve as a docking
platform for downsteam mediators like TAK1 [1]. In this context,
the requirement for TRAF6 autoubiquitination per se has not
been formally demonstrated. We attempted to do so by divorcing
the RING finger function of TRAF6 from its ubiquitin substrate
function. Surprisingly, we found that in the absence of TRAF6
autoubiquitination, IL-1- and RANKL-dependent signaling re-
mained intact in the presence of a functional RING finger domain.
Retrovirally-rescued TRAF6-deficient fibroblasts elaborated IL-6
in response to IL-1, and retrovirally-rescued TRAF6-deficient
BMM developed into osteoclasts in response to RANKL, both
independently of TRAF6 autoubiquitination. TRAF6 autoubiqui-
tination was also found to be dispensable for TRAF6 RING
finger-dependent ubiqutination of NEMO. Further, we found that
neither TRAF6 autoubiquitination, nor the RING finger domain
were required for TRAF6 interaction with the TAK1 complex.
Our initial efforts to identify specific ubiquitin acceptor lysines
on TRAF6 revealed that while we could detect reduced TRAF6
autoubiquitination in some cases, these reductions were not
accompanied by reduced TRAF6 function. This was true even for
TRAF6 K124, the recently identified acceptor site reported to be
essential simultaneously for TRAF6 autoubiquitination and
signaling [22], (Fig. S3). By taking the dramatic step of mutating
all lysines on TRAF6 to arginine in order to ablate all potential
acceptor sites, we were forced to acknowledge certain caveats.
First, some residues may be important for protein stability. While
lysine ablation did not affect expression of N-terminal
TRAF6DK(1-358), full-length DK protein expression was dramat-
ically reduced. Regardless, any loss in protein stability was not
sufficient to affect the signaling functions examined. Second, we
may have inadvertently abrogated the capacity of TRAF6 to
undergo other lysine-dependent modifications, such as acetylation,
methylation, sumoylation, or K48-linked degradative ubiquitina-
tion. Published data indicates a negative regulatory mechanism for
Figure 4. A lysine-deficient mutant TRAF6 rescues RANKL-mediated NFkB and MAPK activation, as well as osteoclastogenesis in
TRAF6-deficient BMM. (A) Wild-type or TRAF6-deficient bone marrow macrophages (BMM) retrovirally-rescued with wild-type (WT), RING mutant
(C70A), or lysine-deficient (DK) full-length versions of FLAG-TRAF6 were treated as indicated with RANKL, then lysed and subjected to
immunoblotting against the activated phosphorylated forms of IkBa, JNK, and p38. B, BMM described in (A) were replated and cultured with M-CSF
and RANKL for 5 days to induce osteoclast differentiation. (C) Osteoclasts depicted in (B) were fixed and subjected to TRAP solution assay and
quantified at 405 nm absorbance. (D) Total cell counts per well of retrovirally-rescued osteoclasts depicted in (B) as defined by cells containing at
least 3 nuclei and being at least 100 mM in diameter.
doi:10.1371/journal.pone.0004064.g004
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somal degradation [30]. Our observation that lysine ablation in
the N-terminus of TRAF6 (Fig. 2) leads to increased NFkB and
AP-1 activity may indicate interference with a similar type of
negative regulation. Additional efforts are required to fully
characterize the effects of this mutational pattern on TRAF6
protein stability and turnover.
Cumulatively, our findings regarding the genetic dispensability
of TRAF6 autoubiquitination lead us to a revised model for
TRAF6-mediated activation of the NFkB and MAPK pathways
(Fig. 7). Upon receptor engagement, K63-linked ubiquitin chains
are affixed to TRAF6, at least in part through the E3 ubiquitin
ligase activity of the TRAF6 RING finger domain. Both TRAF6
autoubiquitination and the TRAF6 RING finger domain appear
dispensable for recruitment of the TAB1-TAB2-TAK1 complex.
Previous reports indicate this interaction to be dependent on the
ability of the TAB2 ubiquitin-binding domain to attach to K63-
linked ubiquitin chains [17], suggesting an unidentified factor
‘‘X’’, which interacts with TRAF6 independently of autoubiqui-
tination, may serve as the binding partner for TAB2. At the same
time, recruitment of TAK1 to TRAF6 is insufficient for TAK1
activation, which specifically requires TRAF6 RING finger
activity. An additional unknown factor ‘‘Y’’ may be indicated, in
this case to serve as a substrate(s) for TRAF6-mediated K63-linked
Figure 5. A lysine-deficient TRAF6 N-terminus-Gyrase B fusion protein remains competent to mediate a TRAF6-specific ubiquitin
modification of NEMO. (A) Wild-type (WT) and TRAF6-deficient (KO) fibroblasts were stimulated for 5 minutes with IL-1b, then lysed with buffer
containing NEM. To determine specificity of in vivo ubiquitination, lysates were dissociated and denatured before being immunoprecipitated with
anti-NEMO. WCE and IP extracts were subjected to immunoblotting with anti-Ubiquitin. (B) 293T cells were transfected with equal amounts (1 mg) of
Myc-tagged NEMO and expression plasmids for TRAF6, TRAF2, TRAF5, constitutively active IKKb (IKKbEE), TAB1 and TAK1, MEKK3, or ASK1. Cells were
lysed in the presence of phosphatase inhibitors and NEM, and WCE were then immunoblotted with anti-NEMO to detect modification of NEMO. (C)
293T cells were transfected with equal amounts (1 mg) of Myc-tagged NEMO and expression plasmids for either wild-type, RING mutant (C70A), or
lysine-deficient FLAG-TRAF6(1-358)-Gyrase B. Cells were lysed in the presence of phosphatase inhibitors and NEM, and WCE were then
immunoblotted with anti-NEMO to detect modification of NEMO. (D) 293T cells were transfected with 10 mg Myc-NEMO and co-transfected with wild-
type or C70A TRAF6(1-358)-Gyrase B (10 mg). These plates, and an untransfected plate, were lysed and immunoprecipitated with anti-Myc agarose. IP
extracts were dissociated from anti-Myc agarose by heating (65uC) in non-reducing SDS-PAGE buffer, and separated from agarose by centrifugation.
Reducing agent was added to IP extracts, and 10% of each was used for immunoblotting with anti-Myc to confirm the presence of NEMO
modification (not shown), while 90% was run on a preparative gel and stained with colloidal coomassie blue (not shown). The NEMO modification
band found in the lane co-transfected with wild-type, but not with C70A TRAF6(1-358)-Gyrase B, was excised, digested with trypsin, and analyzed by
mass spectrometry. Depicted is the m/z profile of the NEMO peptide QEVIDKLKEEAEQHK, for which all detected ions gave predicted values except for
the fragment encompassing lysine 285 between y7 and y8, which exhibits a residue mass of 242.2. This profile is consistent with one lysine and two
glycines, and is indicative of an ubiquitin modification at NEMO K285. (E) 293T cells were transfected with equal amounts (1 mg) of Myc-tagged wild-
type or K285R NEMO in combination with expression plasmids for either wild-type, RING mutant (C70A), or lysine-deficient FLAG-TRAF6(1-358)-Gyrase
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promote TAK1 phosphorylation, leading to MAPK and IKKa/
b activation. TRAF6-mediated activation of the IKKa/b complex
is only partially dependent on TAK1 [31], but exhibits an absolute
requirement for the regulatory component IKKc (NEMO)
[32,33]. NEMO ubiquitination on K285 by TRAF6 is required
for optimal activation of IKKa/b. RING finger-dependent
activation of TAK1 and IKKa/b by TRAF6 might involve
K63-linked ubiquitination of numerous targets, which would
together form a signaling complex sufficient to meet activation
thresholds.
Recent efforts by various groups have identified additional
targets of TRAF6 E3 ubiquitin ligase activity, including IRF-7
downstream of TLRs 7–9 and LMP1 [34,35], IRF-5 downstream
of TLRs 7 and 9 [36], NRIF, TrkA and TrkB, associated with
NGFR [16,37,38], and RIP2 and NEMO downstream of NOD
[7,39]. Intriguingly, in the IL-1R pathway, it has recently been
demonstrated that IRAK-1, which interacts with TRAF6 through
a TRAF6 interaction motif, is modified by K63-linked ubiquitina-
tion in a TRAF6 RING finger-dependent manner [40,41].
Further, it has been shown that NEMO contains a K63-specific
ubiquitin-binding domain, required for IL-1-mediated IKK
activation, which mediates interaction with ubiquitinated IRAK-
1, but not ubiquitinated TRAF6 [40,41]. Examining our data in
this context suggests that IRAK-1 and TRAF6 ubiquitination may
be redundant, or that recruitment of TAK1 via TAB2/3
ubiquitin-binding may be mediated through ubiquitination of
IRAK-1 (and/or one of the alternative TRAF6 targets listed
above) rather than TRAF6. TRAF6 autoubiquitination may, in
fact, be required in the absence of alternative ubiquitin substrates,
or in other signaling systems lacking robust redundancy. Crosstalk
between multiple TRAF6-associated scaffolding systems, specifi-
cally TRAF6-IRAK-NEMO in the IL-1R/TLR pathway and
TRAF6-p62 in the atypical PKC pathway [42], may also create
redundancies which obviate TRAF6 autoubiquitination. Further,
while we have focused here on TRAF6-mediated activation of the
TAK1 pathway, it should be noted that the kinase MEKK3
governs an alternate TRAF6-dependent signaling pathway, for
which the role of TRAF6 autoubiquitination remains unclear [25].
In this study we have undertaken a limited survey of the ever-
expanding array of signaling pathways serviced by TRAF6.
Assessment of the physiologic role of TRAF6 autoubiquitination
may require cell-type specific examination of signals emanating
from TLRs, NLRs, additional TNFRSF members, TGFbR, IL-
17R and IL-25R, and others. However, our data demonstrate that
TRAF6 autoubiquitination is clearly dispensable for TRAF6
function in two key signaling pathways, and suggest that TRAF6-
mediated K63-linked ubiquitination instead targets multiple
relevant protein substrates during activation. Hopefully these
findings will contribute specifically to defining the mechanism of
TRAF6 function, and generally to elucidating the role of non-
conventional ubiquitination in signal transduction.
Materials and Methods
Cell Lines, Reagents, and Antibodies
HEK293 cells were purchased from the American Type Culture
Collection (ATCC). The Plat-E retroviral packaging cell line,
NEMO-deficient fibroblasts, and TAK1-deficient fibroblasts were
kindly provided by T. Kitamura (University of Tokyo), Michael
Karin (UCSD, San Diego), and Sankar Ghosh (Yale University),
respectively. TRAF6-deficient fibroblasts were derived from lung
or peritoneal tissue of E14.5 fetuses. IL-1a and IL-1b were
purchased from R&D Systems (Minneapolis, MN). Soluble
RANKL was purified from insect cells and M-CSF was kindly
provided by David Fremont (Washington University, St. Louis,
MO). TRAP solution substrate and Coumermycin A were
purchased from Sigma (St. Louis, MO). Antibodies specific for
FLAG (M2 and M5) and Myc (9E12) were from Sigma (St. Louis,
MO); for phospho-TAK1 (T187), phospho-p38, phospho-IkBa,
phospho-IKKa/b,I kBa, p38, JNK, TAK1, IKK, and NEMO
were from Cell Signaling (Danvers, MA); for TRAF6 was from
MBL (Tokyo, Japan); for phospho-JNK was from BD Biosciences
(Franklin Lakes, NJ); and for Ubiquitin was from Millipore
(Billerica, MA).
Plasmids
Murine TRAF2, TRAF5, and TRAF6 were cloned into the
NotI and BamHI sites of CMV2-pFLAG (Sigma; St. Louis, MO).
Gyrase B-pEF was kindly provided by Jun-ichiro Inoue (University
of Tokyo). TRAF6 N-terminus-Gyrase B fusion constructs were
made by cloning Gyrase B into an EcoRI site downstream of and
in frame with TRAF6(1-358) and the BamHI site. Various TRAF6
and NEMO point mutations were generated by PCR using the
Figure 6. Ubiquitination of NEMO by TRAF6 is partially required for IL-1-mediated activation of NFkB. (A) NEMO-deficient fibroblasts
retrovirally-rescued with wild-type or K285R NEMO were treated as indicated with IL-1b, then lysed and subjected to immunoblotting against the
activated phosphorylated forms of TAK1, IKKa/b, and IkBa. (B) NEMO-deficient fibroblasts retrovirally-rescued with WT or K285R NEMO were left
untreated or treated for 12 hours with IL-1b. Supernatants were collected and assayed by ELISA for IL-6 production. Values are normalized to crystal
violet assays of the cell culture plates.
doi:10.1371/journal.pone.0004064.g006
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kit. Murine splenic cDNA was used to clone TAK1, TAB1, TAB2,
and MEKK3 by PCR into pcr2.1 using Zero Blunt Topo, and
subcloned into pcDNA3.1-MycHis (Invitrogen; Carlsbad, CA).
FLAG-NEMO and FLAG-IKKbEE were kindly provided by
Michael May (University of Pennsylvania). FLAG-ASK1 was
kindly provided by Eui-Ju Choi (Korea University).
Cell Culture, Transfections and Retroviral Transduction
5610
6 293T and plat-E cells were cultured in DMEM
supplemented with 10% FBS, penicillin/streptomycin (all pur-
chased from Invitrogen; Carlsbad, CA) in 10 cm tissue culture-
treated dishes. Cells were transfected with 15 mL Superfect
(Qiagen; Venlo, Netherlands) plus DNA cocktails for 2 hours,
then washed with fresh medium, and cultured for an additional
36 hours before harvesting cells or supernatants. Retroviral
supernatants were harvested after 36 hours transfection, mixed
1:1 with fresh medium, and added to cells to be transduced with
5 mg/mL polybrene (Sigma; St. Louis, MO) for 6 hours. 24 hours
post-transduction, infected cells were replated in fresh medium
containing 2 mg/mL puromycin for 2 days selection.
Immunoprecipitation and Western Blotting
Cells were harvested with ice-cold PBS and scraping, pelleted,
and lysed with 1 mL lysis buffer (20 mM HEPES buffer pH 7.5,
150 mM NaCl, 10% (w/v) glycerol, protease inhibitor cocktail
(Roche; Basel, Switzerland), 2 mM sodium ortho-vanadate, 2 mM
NaF, 100 ng/mL Calyculin A (Cell Signaling; Danvers, MA),
1.25 mg/mL N-Ethyl Malemide (Sigma; St. Louis, MO)) with
1.0% (w/v) Triton-6100 or 0.5% NP-40 (for immunoprecipita-
tion). Lysates were incubated on ice for 20 minutes, and clarified
by centrifugation at 20,0006g for 10 minutes. Whole cell extracts
were aliquotted, added to 66 SDS loading buffer and boiled.
Extracts for in vivo ubiquitination analysis were first boiled with
10% SDS for 10 minutes, then diluted 10-fold with lysis buffer.
Otherwise, extracts for IP were transferred to 50 mL anti-FLAG or
anti-Myc agarose (Sigma, St. Louis, MO), and incubated while
rocking at 4uC for 3 hours. IP agarose beads were washed 36with
lysis buffer, resuspended in SDS loading buffer and boiled.
Samples were run on 10% SDS-PAGE and transferred to PVDF
membrane (Millipore; Billerica, MA). Blots were probed with
primary antibodies in 5% milk dissolved in PBS with 0.1% Tween-
20, followed by secondary anti-rabbit-HRP or anti-mouse-HRP
(Promega; Madison, WI). Western blots were incubated with ECL
substrate (Pierce; Rockford, IL) and exposed to film.
In Vitro Ubiquitination
Assays were performed in 30 mL reactions with buffer
containing 300 mM HEPES at pH 7.2, 50 mM MgCl2 and
2 mM dithiothreitol. Additional components included 0.15 mg
recombinant rabbit E1 activating enzyme (Boston Biochem) and
0.6 mg recombinant mouse Ubc13/Uev1a conjugating complex
(Boston Biochem). 2.5 mg recombinant ubiquitin (Boston Bio-
chem) containing all lysines, K48 only, or K63 only was added as
indicated. 20 mM ATP was added as indicated. Ubiquitin E3
ligase/substrate was prepared as a 50 mL IP of cell lysates
containing the indicated version of FLAG-tagged TRAF6, from
which 15 mL was added to a 26reaction cocktail. Reactions were
incubated for 1 hour at 30uC with 450 rpm shaking, and then
washed 36 with buffer alone to separate unincorporated
components from IP beads containing the TRAF6 substrate.
Osteoclast Cultures
Bone marrow stem cells were flushed from femurs and tibias of
chimeric mice reconstituted with liver cells harvested from wild-
type or TRAF6-deficient E14.5 fetuses, and cultured with M-CSF
(30 ng/ml) for 5 days in a-minimal essential medium (a-MEM)
containing 10% fetal bovine serum. Attached cells were trans-
duced with retrovirus on day 2 and replated on day 3 for 48 hours
selection with puromycin (2 mg/mL). Selected bone marrow
macrophages (BMM) were replated on day 5 in 96-well plates
(2610
4/well) with fresh medium supplemented with M-CSF
(30 ng/ml) and RANKL (100 ng/ml) for 4 days (medium and
cytokines refreshed after 2 days) to induce osteoclastogenesis. For
TRAP solution assays, cells were fixed with 10% formalin,
permeabilized with methanol/acetone (1:1), dried, and then
incubated with TRAP substrate solution for 30 minutes at room
temperature. Substrate solution was mixed 2:1 with 1N NaOH,
and quantified by 405 nm absorbance. Osteoclast cell counts were
determined by enumerating TRAP+ cells larger than 100 mmi n
diameter with more than three nuclei in each well.
Figure 7. A revised model for TRAF6-dependent activation of
the MAPK and IKK signaling pathways in the absence of TRAF6
autoubiquitination. Upon receptor engagement, K63-linked ubiqui-
tin chains are affixed to TRAF6, at least in part through the E3 ubiquitin
ligase activity of the TRAF6 RING finger domain. Both TRAF6
autoubiquitination and the TRAF6 RING finger domain appear
dispensable for recruitment of the TAB1-TAB2-TAK1 complex. Previous
reports indicate this interaction to be dependent on the ability of the
TAB2 ubiquitin-binding domain to attach to K63-linked ubiquitin chains
[17], suggesting an unidentified factor ‘‘X’’, which interacts with TRAF6
independently of autoubiquitination, may serve as the binding partner
for TAB2. At the same time, recruitment of TAK1 to TRAF6 is insufficient
for TAK1 activation, which specifically requires TRAF6 RING finger
activity. An additional unknown factor ‘‘Y’’ may be indicated, in this case
to serve as a substrate(s) for TRAF6-mediated K63-linked ubiquitination.
Upon being ubiquitinated, factor ‘‘Y’’ would promote TAK1 phosphor-
ylation, leading to MAPK and IKKa/b activation. TRAF6-mediated
activation of the IKKa/b complex is only partially dependent on TAK1
[31], but exhibits an absolute requirement for the regulatory
component IKKc (NEMO) [32,33]. NEMO ubiquitination on K285 by
TRAF6 is required for optimal activation of IKKa/b. RING finger-
dependent activation of TAK1 and IKKa/b by TRAF6 might involve
K63-linked ubiquitination of numerous targets, which together form a
signaling complex sufficient to meet activation thresholds. TRAF6
autoubiquitination may, in fact, be required in the absence of
alternative ubiquitin substrates, or in as yet untested signaling systems
lacking robust redundancy. This schematic underscores the point that
in contrast to the absolute requirement for TRAF6 RING finger E3 ligase
activity in mediating downstream signaling, K63-linked ubiquitination
of TRAF6 should be viewed as a marker of activation.
doi:10.1371/journal.pone.0004064.g007
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HEK293 cells were transfected in triplicate with test plasmids
plus 50 ng luciferase reporter plasmid and 10 ng b-Galactosidase
control plasmid in 6-well plates. Cells were harvested and lysed
with Tropix Lysis Buffer (Applied Biosystems; Foster City, CA).
Lysates were freeze-thawed 36before clarification by centrifuga-
tion. 15 mL of lysate was mixed with Tropix substrate for
30 minutes, added to 100 mL Tropix accelerator and b-Galacto-
sidase assayed colorimetrically. 15 mL of lysate was mixed with
100 mL luciferase substrate (Promega; Madison, WI), and assayed
colorimetrically for reporter activity. Reporter activity was
normalized to b-Galactosidase levels.
Mass Spectrometry
Proteins from gel bands were digested with modified trypsin,
and peptides analyzed by microflow reverse phase-HPLC/MS/
MS with a ThermoFinnigan LCQ Deca XP LTQ-OrbitrapXL
Mass Spectrometer with Nano-capillary HPLC operated in
positive-ion mode at a flow-rate of 250 nl/min and a 75 mm
(ID)615 mm65 cm C18 column. SEQUEST (ThermoFinnigan,
San Jose, CA) software was used to identify all MS/MS data for
NEMO modified lysine residues corresponding to an ubiquitin
modification (GG, 114.1 Da).
Supporting Information
Figure S1 In vitro autoubiquitination of TRAF6 is RING
finger-dependent . 293T cells were transfected with FLAG-
TRAF6 or FLAG-TRAF6 C85A/H87A, immunoprecipitated
with FLAG, and lysates subjected to in vitro ubiquitination in
the presence or absence of ATP using biotinylated recombinant
ubiquitin. Unmodified TRAF6 was detected by immunoblotting
with anti-TRAF6 and polyubiquitination was detected with
streptavidin-HRP (SA-HRP).
Found at: doi:10.1371/journal.pone.0004064.s001 (0.63 MB TIF)
Figure S2 TAK1 T187 is required for optimal IL-1-dependent
NFkB and MAPK signaling. TAK1-deficient fibroblasts were
retrovirally-rescued with empty vector, wild-type TAK1, or TAK1
T187A were treated as indicated with IL-1b, then lysed and
subjected to immunoblotting against the activated phosphorylated
forms of IkBa and JNK.
Found at: doi:10.1371/journal.pone.0004064.s002 (1.05 MB TIF)
Figure S3 TRAF6 K124 is not required for IL-1-dependent
NFkB and MAPK signaling. TRAF6-deficient fibroblasts were
retrovirally-rescued with the indicated full-length versions of
TRAF6, including one containing a single lysine to arginine
mutation at K124, and treated as indicated with IL-1b, then lysed
and subjected to immunoblotting against the activated phosphor-
ylated forms of IkBa or JNK.
Found at: doi:10.1371/journal.pone.0004064.s003 (1.13 MB TIF)
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